 | | Vol. 24.25 – 24 July, 2023 |
| |
|
|
| Investigators developed ARF-mimetic MDM2-targeting reassembly peptide nanoparticles (MtrapNPs) for p53-based tumor therapy. They elucidated that the MtrapNPs responded to and formed a nanofiber structure with MDM2.
[Advanced Materials] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To increase the selectivity of CD229 CAR T cells for multiple myeloma cells, scientists used a single amino acid substitution approach of the CAR binding domain to reduce CAR affinity.
[Science Translational Medicine] |
|
|
|
| The authors screened a diverse library of ionizable lipid nanoparticles (LNPs) via intracerebroventricular injection in both fetal and neonatal mice and identified an LNP formulation with greater functional mRNA delivery in the perinatal brain than an FDA-approved industry standard LNP.
[ACS Nano] |
|
|
|
| Researchers showed that the spatiotemporal distribution of Gli1+ cells in tissue engineering blood vessels (TEBVs) was positively correlated with the degree of TEBV calcification.
[Science Advances] |
|
|
|
| The authors constructed a MSC–based nanoengineered platform via the bioconjugation of MSCs and type I collagenase–modified liposomes loaded with nintedanib for treating severe fibrosis.
[Science Advances] |
|
|
|
| Researchers uncovered epigenetic alterations in diabetic vs non-diabetic human limbal epithelial cells enriched in limbal epithelial stem cell and identified new diabetic markers that could be targeted for therapy to normalise corneal epithelial wound healing and stem cell expression.
[Diabetologia] |
|
|
|
| Scientists presented the preclinical development of a novel FMS-like tyrosine kinase 3 (FLT3)-directed UniCAR T-cell therapy showing both in vitro and in vivo functionality.
[British Journal Of Haematology] |
|
|
|
| Investigators utilized non-viral technology to achieve early termination of CAR T cell activity to prevent incoming graft rejection.
[Molecular Therapy Oncolytics] |
|
|
|
| Scientists analyzed data from five adults with B cell acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic stem cell transplantation and received donor-derived CAR-T cell therapy donor-derived peripheral blood stem cells.
[European Journal Of Haematology] |
|
|
|
|
| Investigators summarize recent advances in biomaterials for in situ cell therapy including T cells, macrophages, dendritic cells, and stem cells reprogramming leveraging lipid nanoparticles, polymers, inorganic materials, and other biomaterials.
[BMEMat] |
|
|
|
|
| Replay and The University of Texas MD Anderson Cancer Center announced that the US FDA has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, a first-in-class engineered TCR-NK cell therapy for relapsed or refractory multiple myeloma.
[Replay Bio] |
|
|
|
|
| August 25 – 28, 2023
Amsterdam, Netherlands & Virtual |
|
|
|
|
|
| | NICHD – Bethesda, Maryland, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Maastritch University – Maastricht, Netherlands |
|
|
|
| | NCI Center for Cancer Research – Bethesda, Maryland, United States |
|
|
|
| | Institute of Biology Valrose – Nice, France |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
